Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, SOMAR and Litha– Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals.
Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success.
Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 4,900 people worldwide*.
*As of 2/21/2017